NCT04238936

GDM Patients and Serum Amyloid A and Interleukin-1 (IL-1) Receptor Antagonist

Levels of New Inflammatory Markers in GDM Patients; Serum Amyloid A and Interleukin-1 (IL-1) Receptor Antagonist

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 80 (actual)
• Sponsor: Kanuni Sultan Suleyman Training and Research Hospital · Academic / Other
• Sex: Female
• Age: 18 Years – 42 Years
• Healthy volunteers: Accepted

Summary

Serum amyloid A and Interleukin-1 (IL-1) receptor antagonist (A-SAA and IL-1Ra) values; * Comparison of pregnant women with and without GDM diagnosis * Comparison of insulin therapy and diet-regulated GDM patients * Comparison of pregnant women with and without LGA (large gestational age) * Comparison of pregnant women with and without polyhydroamnios * Investigation of its effect on pregnancy prognosis * In the prediction of GDM diagnosis, it is aimed to study the sensitivity and specificity of both parameters and cut off values. (In GDM patients, liver and kidney function parameters will also be evaluated with A-SAA and IL-1Ra levels).

Conditions

• Gestational Diabetes

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	Serum amyloid A values	Women who are diagnosed with GDM between the ages of 18 and 43 will receive blood in the biochemistry tube. This tube will then be centrifuged. A-SAA and IL-1Ra levels will be checked by ELISA method in serum stored at -80 degrees.
DIAGNOSTIC_TEST	Interleukin-1 (IL-1) receptor antagonist values (A-SAA and IL-1Ra)	Women who are diagnosed with GDM between the ages of 18 and 43 will receive blood in the biochemistry tube. This tube will then be centrifuged. A-SAA and IL-1Ra levels will be checked by ELISA method in serum stored at -80 degrees.

Timeline

• Start date: 2020-01-20
• Primary completion: 2020-05-20
• Completion: 2020-05-20
• First posted: 2020-01-23
• Last updated: 2020-05-22

Locations

1 site across 1 country: Turkey (Türkiye)